Language:

Le médicament du moisMavacamten (Camzyos®) : premier inhibiteur réversible de l’ATP-ase de la myosine pour le traitement des cardiomyopathies hypertrophiques obstructives

ISSN: 2566-1566 ;ISSN: 0370-629X ;PMID: 38356430

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Le médicament du moisMavacamten (Camzyos®) : premier inhibiteur réversible de l’ATP-ase de la myosine pour le traitement des cardiomyopathies hypertrophiques obstructives
Author: Lancellotti, Patrizio ; de Marneffe, Nils ; Scheen, André
Subjects: 56HH86ZVCT (Uracil) ; Adult ; Benzylamines ; Benzylamines/adverse effects ; Cardiomyopathy, Hypertrophic/drug therapy ; Cardiovascular & respiratory systems ; Dynamic obstruction ; EC 3.6.4.1 (Myosins) ; Human health sciences ; Humans ; Hypertrophic cardiomyopathy ; Mavacamten ; MYK-461 ; Myosin modulator ; Myosins ; Sciences de la santé humaine ; Stroke Volume ; Systèmes cardiovasculaire & respiratoire ; Treatment ; United States ; Uracil/analogs & derivatives ; Ventricular Function, Left
Description: Mavacamten (Camzyos®) is a myosin modulator which reduces the interactions between myosin and actin. These are overly activated in hypertrophic cardiomyopathy (HCM), a source of exaggerated ventricular contractility, energy loss, and impairment of diastolic function (relaxation). The Food and Drug Administration (FDA) and the European Medication Agency (EMA) approved mavacamten for the treatment of symptomatic obstructive HCM (NYHA class II or III) in adult patients in 2022 and 2023, respectively. The medication is not yet reimbursed in Belgium. As seen in its clinical development studies, mavacamten reduces the intraventricular gradient, improves functional capacity and reduces symptoms. It also seems to be an innovative alternative to septal reduction. Mavacamten is usually very well tolerated knowing that, through its mechanism of action, it causes a dose-dependent and reversible reduction in left ventricular ejection fraction, which must therefore be closely monitored. The good tolerance and the effectiveness of mavacamten seem to be maintained over time. Consequently, the recent European Society of Cardiology Updated Guidelines on cardiomyopathy (ESC 09/2023) already recommend mavacamten in the pharmacological management of obstructive HCM.
Publisher: Université de Liège. Revue Médicale de Liège
Creation Date: 2024
Language: French
Identifier: ISSN: 2566-1566
ISSN: 0370-629X
PMID: 38356430
Source: Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Le médicament du moisMavacamten (Camzyos®) : premier inhibiteur réversible de l’ATP-ase de la myosine pour le traitement des cardiomyopathies hypertrophiques obstructives

ISSN: 2566-1566 ;ISSN: 0370-629X ;PMID: 38356430

Searching Remote Databases, Please Wait